Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...
Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions ...
Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback